Clinical trial
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in…
NCT00174291 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00174291 |
|---|---|
| Title | Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy |
| Official title | Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Endocrine System Diseases |
| Intervention type | Drug |
| Interventions | Somatropin |
| Enrollment | 21 |
| Start date | Mar 1, 2002 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 4, 2012 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: